Amycretin and CagriSema are both Novo Nordisk obesity programs that pair GLP-1 with amylin, two appetite hormones, but they go about it differently. CagriSema combines two separate molecules (semaglutide plus cagrilintide) in one weekly injection and has already been submitted to the FDA. Amycretin packs both actions into a single molecule and comes as both a weekly shot and a daily pill, though it sits earlier in testing. Neither is FDA approved yet, and neither is available through TrimRx or anywhere else outside of clinical trials.<\/p>\n
CagriSema is a fixed-dose combination of semaglutide 2.4 mg (the GLP-1 drug in Wegovy) and cagrilintide 2.4 mg (a long-acting amylin analog), given as one weekly subcutaneous injection. Amylin is a hormone that signals fullness and slows stomach emptying, working alongside GLP-1 rather than duplicating it.<\/p>\n
Novo Nordisk submitted CagriSema to the FDA in December 2025, based on its REDEFINE Phase 3 program, with a decision expected by late 2026. In REDEFINE 1 (adults with obesity, no diabetes), CagriSema produced about 20.4% mean weight loss at 68 weeks, rising to 22.7% among people who stuck with treatment, compared with roughly 16% for semaglutide alone. That beat semaglutide but fell short of Novo’s pre-trial target of around 25%. A later head-to-head trial, REDEFINE 4, pitted CagriSema against tirzepatide (Zepbound), and the combination did not match it: about 23% versus 25.5% weight loss at 84 weeks, missing its goal of proving it was no worse than the approved drug.<\/p>\n
Amycretin takes the same two targets, GLP-1 and amylin, and builds them into one molecule instead of combining two drugs. That single-molecule design is the technical distinction Novo Nordisk is pursuing, and it allows amycretin to be developed in two forms: a once-weekly injection and a once-daily oral tablet.<\/p>\n
The early data is promising but comes from smaller, earlier-stage trials. In a Phase 1b\/2a study of adults with overweight or obesity, injectable amycretin produced estimated weight loss of about 22% at 36 weeks on the highest dose, with no plateau by the study’s end. In November 2025, Novo Nordisk reported Phase 2 results in people with type 2 diabetes, where the injection led to up to about 14.5% weight loss and the pill up to about 10.1% over 36 weeks (people with diabetes typically lose less than those without). Based on these results, both formulations are moving into Phase 3 testing in 2026, alongside the rest of the obesity drug pipeline<\/a>.<\/p>\n The headline contrast is structural. CagriSema is two drugs in one pen, which means the dose of each component is set by the combination. Amycretin folds both actions into a single molecule, which in theory simplifies the chemistry and the dosing. Whether one molecule outperforms two in practice is still an open question, and it’s the kind of thing Phase 3 trials exist to answer.<\/p>\n This is where amycretin stands apart. CagriSema is injection-only. Amycretin is being developed as both an injection and a daily oral tablet. An effective oral option matters for people who would rather avoid weekly shots, and amycretin’s early oral numbers run ahead of what current GLP-1 pills deliver. The catch is that the pill’s results so far trail the injectable version of the same drug.<\/p>\n CagriSema is much closer to the finish line. It’s already under FDA review, so if approved it could reach the market well before amycretin. Amycretin is just starting Phase 3 in 2026, which puts any potential approval years out, likely 2028 at the earliest. So while amycretin may look intriguing on paper, CagriSema is the one with a near-term decision pending.<\/p>\n Comparing the percentages directly is tricky, since the trials differ in size, length, and patient population. CagriSema has large, late-stage data landing in the low 20s percent for weight loss, though it underwhelmed against its own targets and against tirzepatide. Amycretin’s headline 22% comes from a small, early study, so it carries more uncertainty. The fair summary: CagriSema has the deeper evidence, amycretin has the more flexible design and a longer road ahead.<\/p>\n Both drugs are investigational. CagriSema is awaiting an FDA decision, and amycretin is still in mid-stage development, so neither can be prescribed, and neither is available as a compounded product (compounding applies to approved medications, which these are not). Any “research-grade” peptide marketed online as amycretin or a cagrilintide combination sits outside pharmacy oversight, with no assurance of purity, sterility, or correct dosing, and isn’t a safe or legal substitute. The trial doses noted here are what researchers used under supervision, not a plan to follow on your own.<\/p>\n If you’re trying to decide between waiting and starting, remember that effective, approved options already exist. Tirzepatide and semaglutide both produce meaningful weight loss now, and notably, tirzepatide outperformed CagriSema in a direct trial. There’s little reason to wait years for a pipeline drug when proven treatments are available today, and what tirzepatide can do week by week<\/a> is well documented. Switching later is straightforward if a better option arrives, a dynamic playing out across the whole GLP-1 market<\/a>.<\/p>\nAmycretin vs CagriSema at a Glance<\/h3>\n
\n\n
\n \nFeature<\/th>\n Amycretin<\/th>\n CagriSema<\/th>\n<\/tr>\n<\/thead>\n \n Maker<\/td>\n Novo Nordisk<\/td>\n Novo Nordisk<\/td>\n<\/tr>\n \n Design<\/td>\n GLP-1 + amylin in one molecule<\/td>\n GLP-1 + amylin, two molecules combined<\/td>\n<\/tr>\n \n Form<\/td>\n Injectable and oral<\/td>\n Injectable only<\/td>\n<\/tr>\n \n Dosing<\/td>\n Weekly shot or daily pill<\/td>\n Weekly shot<\/td>\n<\/tr>\n \n Stage<\/td>\n Entering Phase 3 (2026)<\/td>\n Submitted to FDA (Dec 2025)<\/td>\n<\/tr>\n \n Weight loss<\/td>\n ~22% at 36 weeks (early study)<\/td>\n ~20% to 23% at 68-84 weeks (Phase 3)<\/td>\n<\/tr>\n \n FDA status<\/td>\n Investigational<\/td>\n Under FDA review<\/td>\n<\/tr>\n \n Available now?<\/td>\n No<\/td>\n No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n The Real Differences<\/h3>\n
One molecule versus two<\/h4>\n
The pill factor<\/h4>\n
How far along each one is<\/h4>\n
What the efficacy picture suggests<\/h4>\n
Why Neither Is Available Yet<\/h3>\n
What You Can Do Today<\/h3>\n